{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:federal-register-2026-12937:v1","objectPathId":"federal-register-2026-12937-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/federal-register-2026-12937/","json":"https://peptidescanner.com/evidence/v1/objects/federal-register-2026-12937-v1.json","markdown":"https://peptidescanner.com/evidence/v1/objects/federal-register-2026-12937-v1.md"},"story":{"slug":"federal-register-2026-12937","version":1,"domain":"Regulatory","dateInSource":"2026-06-26","sourceCheckedAt":"2026-08-21","publishedAt":"2026-08-21","peptideSlugs":["liraglutide","semaglutide","tirzepatide"],"peptides":[{"slug":"liraglutide","url":"https://peptidescanner.com/peptides/liraglutide/"},{"slug":"semaglutide","url":"https://peptidescanner.com/peptides/semaglutide/"},{"slug":"tirzepatide","url":"https://peptidescanner.com/peptides/tirzepatide/"}]},"claims":[{"id":"headline","text":"Federal Register notice 2026-12937","sourceIds":["federal-register-2026-12937-2818b85377d3"]},{"id":"summary","text":"The Federal Register published notice 2026-12937, attributed to FDA and its parent HHS department, on 2026-06-26. Its official title is “List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Period,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide, Semaglutide and Tirzepatide.","sourceIds":["federal-register-2026-12937-2818b85377d3"]},{"id":"paragraph-1","text":"The Federal Register published notice 2026-12937, attributed to FDA and its parent HHS department, on 2026-06-26. Its official title is “List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Period,” and PeptideScanner's exact reviewed identity mapping connects the document to Liraglutide, Semaglutide and Tirzepatide.","sourceIds":["federal-register-2026-12937-2818b85377d3"]},{"id":"paragraph-2","text":"This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use.","sourceIds":["federal-register-2026-12937-2818b85377d3"]}],"sources":[{"id":"federal-register-2026-12937-2818b85377d3","name":"Federal Register via GovInfo","sourceClass":"A","title":"Federal Register notice 2026-12937 · published 2026-06-26 · List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act; Extension of Comment Period","url":"https://www.govinfo.gov/content/pkg/FR-2026-06-26/pdf/2026-12937.pdf"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"e6381a9cb046229658701d3d238d0340cebb70086b3da068d3305ebce0114121","tierARecordSha256":"2818b85377d39471d84f2978714e0fa5a3c821286d10f02ac8172bc55722989c"},"integrity":{"algorithm":"sha256","contentSha256":"7710cb5358e0a84999cae4b6e023411dd3326654d801799a98fe07bcf5c85cbe"}}